[an error occurred while processing the directive]
RSS
Логотип
Баннер в шапке 1
Баннер в шапке 2

Habana Labs

Company

width=200px

Owners:
Intel

Content

Owners

Habana Labs — the developer of processors founded in 2016 for a training of artificial intelligence. The headquarters of the company is in Tel Aviv.

History

2019: Intel purchased Habana Labs for $2 billion

On December 16, 2019 Intel announced purchase of Habana Labs for $2 billion to strengthen positions in the world market AI- processors which amount, as expected, will exceed $25 billion to the 2024th.

By December, 2019 in a portfolio of Habana two main products are provided: eight-nuclear Gaudi and Goya processors. The first of them is intended only for training of AI models. He, according to the company, trains models of machine learning in comparison with the flagman video card for data centers of Nvidia V100 3.8 times quicker.

Intel announced purchase of Habana Labs for $2 billion

The Goya chip is adapted for mechanisms of logical training, i.e. under start of AI models when they are already trained and began to work with real data. The processor is used by operators of hyper scalable data centers and developers of unmanned vehicles.

File:Aquote1.png
Habana will quickly load our AI products for DPCs by means of family of the high-performance training processors and the standardized coding environment which are intended for new AI-applications — the executive vice president and the head of department of Intel Data Platforms Group Navin Shena (Navin Shenoy) said.
File:Aquote2.png

Under the terms of the agreement, the part of independent business division Intel will be assigned to Habana company. The headquarters of Habana will remain in Israel, and the management team of a startup will save structure.

Purchase of Habana became a part of strategy of Intel on strengthening of the positions in the market of artificial intelligence technologies. The corporation expects to earn more than $3.5 billion at the end of 2019 from the relevant decisions that for 20% exceeds an indicator of year prescription.[1]

Notes